Advertisement

Trastuzumab Deruxtecan vs Trastuzumab Emtansine in Previously Treated Metastatic HER2-Positive Breast Cancer
Posted: 04/06/2022 | By: Matthew Stenger

Question 1 of 5

The DESTINY-Breast03 trial compared the efficacy and safety of trastuzumab deruxtecan (a HER2 antibody-drug conjugate) vs trastuzumab emtansine in patients with HER2-positive metastatic breast cancer. Study enrollment required:

Choose 1

A
Treatment with four or more prior lines of systemic therapy
B
No prior treatment
C
Prior treatment with trastuzumab and a taxane
D
No history of trastuzumab treatment

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage